Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.

Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, Bianconi F.

Oncotarget. 2017 Jun 14;8(47):83343-83353. doi: 10.18632/oncotarget.18480. eCollection 2017 Oct 10.

2.

Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.

Ummanni R, Mannsperger HA, Sonntag J, Oswald M, Sharma AK, König R, Korf U.

Biochim Biophys Acta. 2014 May;1844(5):950-9. doi: 10.1016/j.bbapap.2013.11.017. Epub 2013 Dec 19.

3.

The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.

Dogan Turacli I, Ozkan AC, Ekmekci A.

Tumour Biol. 2015 Dec;36(12):9339-45. doi: 10.1007/s13277-015-3671-0. Epub 2015 Jun 25.

PMID:
26108998
4.

Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.

Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV.

J Thorac Oncol. 2010 Dec;5(12):1894-904. doi: 10.1097/JTO.0b013e3181f2a266.

5.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

6.

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.

Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX, Zhou SF.

Drug Des Devel Ther. 2015 Mar 12;9:1555-84. doi: 10.2147/DDDT.S74197. eCollection 2015.

7.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

8.

Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.

Hülsmann HJ, Rolff J, Bender C, Jarahian M, Korf U, Herwig R, Fröhlich H, Thomas M, Merk J, Fichtner I, Sültmann H, Kuner R.

Lung Cancer. 2014 Nov;86(2):151-7. doi: 10.1016/j.lungcan.2014.09.001. Epub 2014 Sep 10.

PMID:
25240516
9.

Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy.

An SJ, Huang YS, Chen ZH, Han JF, Yang JJ, Zhou Q, Xie Z, Yang Y, Yan HH, Wu YL.

Cancer Gene Ther. 2014 Mar;21(3):110-4. doi: 10.1038/cgt.2014.5. Epub 2014 Feb 28.

PMID:
24577128
10.

Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light.

Einspahr JG, Curiel-Lewandrowski C, Calvert VS, Stratton SP, Alberts DS, Warneke J, Hu C, Saboda K, Wagener EL, Dickinson S, Dong Z, Bode AM, PetricoinIII EF.

NPJ Precis Oncol. 2017;1. pii: 34. doi: 10.1038/s41698-017-0037-7. Epub 2017 Sep 21.

11.

Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.

Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.

PLoS One. 2012;7(2):e31331. doi: 10.1371/journal.pone.0031331. Epub 2012 Feb 15.

12.

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists.

Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24.

PMID:
26209642
13.

Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy.

Tsakiridis T, Cutz JC, Singh G, Hirte H, Okawara G, Corbett T, Sur R, Cai W, Whelan T, Wright JR.

J Thorac Oncol. 2008 Jul;3(7):716-22. doi: 10.1097/JTO.0b013e31817c6094.

14.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G.

J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13.

15.

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Lung Cancer. 2013 Mar;79(3):312-7. doi: 10.1016/j.lungcan.2012.11.016. Epub 2012 Dec 11.

PMID:
23238036
16.

Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.

Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M.

Anticancer Res. 2012 Nov;32(11):5003-10.

PMID:
23155271
17.

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.

Coco S, Truini A, Alama A, Dal Bello MG, Venè R, Garuti A, Carminati E, Rijavec E, Genova C, Barletta G, Sini C, Ballestrero A, Boccardo F, Grossi F.

Target Oncol. 2015 Sep;10(3):393-404. doi: 10.1007/s11523-014-0344-7. Epub 2014 Oct 25.

PMID:
25341405
18.

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.

VanMeter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF 3rd, Liotta LA, Espina V.

Mol Cell Proteomics. 2008 Oct;7(10):1902-24. doi: 10.1074/mcp.M800204-MCP200. Epub 2008 Aug 6.

20.

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.

Han K, Claret L, Sandler A, Das A, Jin J, Bruno R.

BMC Cancer. 2016 Jul 13;16:473. doi: 10.1186/s12885-016-2455-2.

Supplemental Content

Support Center